BLFS vs. ATRI, AVTE, ELVN, IRON, EOLS, TMCI, MD, PRTC, TNGX, and ACCD
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Atrion (ATRI), Aerovate Therapeutics (AVTE), Enliven Therapeutics (ELVN), Disc Medicine (IRON), Evolus (EOLS), Treace Medical Concepts (TMCI), Pediatrix Medical Group (MD), PureTech Health (PRTC), Tango Therapeutics (TNGX), and Accolade (ACCD). These companies are all part of the "medical" sector.
Atrion (NASDAQ:ATRI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability.
Atrion has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Atrion has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
66.2% of Atrion shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 22.7% of Atrion shares are owned by company insiders. Comparatively, 2.7% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Atrion had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 4 mentions for Atrion and 3 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.73 beat Atrion's score of 0.52 indicating that Atrion is being referred to more favorably in the media.
BioLife Solutions received 171 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 66.82% of users gave BioLife Solutions an outperform vote while only 56.09% of users gave Atrion an outperform vote.
BioLife Solutions has a consensus target price of $23.40, suggesting a potential upside of 49.23%. Given Atrion's higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Atrion.
Atrion has a net margin of 11.46% compared to Atrion's net margin of -46.37%. BioLife Solutions' return on equity of 8.07% beat Atrion's return on equity.
Summary
Atrion beats BioLife Solutions on 10 of the 17 factors compared between the two stocks.
Get BioLife Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
Related Companies and Tools
